Safety Alerts and Products Recalls > ADRs that result in revision of product information on suspension of marketing authorisation

ADR that result in revision of patient information   Australia: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists       Attachment: Australia: Medicines containing GLP-1 and dual GIP/GLP-1 receptor agonists   Related Information: United Kingdom: GLP-1 and dual GIP/GLP-1 receptor agonists: potential risk of pu... Posted 2025-02-01 New recommendations for GLP-1 receptor agonists to minimise risk of aspiration a... Posted 2024-07-15 European Union: New recommendations for GLP-1 receptor agonists to minimise risk... Posted 2024-07-13